Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2002 2
2003 1
2004 2
2006 9
2007 8
2008 4
2009 4
2010 4
2011 9
2012 12
2013 14
2014 19
2015 18
2016 16
2017 15
2018 15
2019 22
2020 17
2021 24
2022 35
2023 45
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Tan HC, Dampil OA, Marquez MM. Tan HC, et al. J ASEAN Fed Endocr Soc. 2022;37(2):65-72. doi: 10.15605/jafes.037.02.14. Epub 2022 Aug 23. J ASEAN Fed Endocr Soc. 2022. PMID: 36578889 Free PMC article. Review.
Serious events were mostly of gastrointestinal and hepatobiliary disorders such as acute pancreatitis and cholelithiasis. CONCLUSION: Among individuals with obesity without type 2 diabetes, subcutaneous semaglutide is effective for weight loss with an 11.85% reduction from …
Serious events were mostly of gastrointestinal and hepatobiliary disorders such as acute pancreatitis and cholelithiasis. CONCLUSION: …
Open versus laparoscopic cholecystectomy in acute cholecystitis. Systematic review and meta-analysis.
Coccolini F, Catena F, Pisano M, Gheza F, Fagiuoli S, Di Saverio S, Leandro G, Montori G, Ceresoli M, Corbella D, Sartelli M, Sugrue M, Ansaloni L. Coccolini F, et al. Int J Surg. 2015 Jun;18:196-204. doi: 10.1016/j.ijsu.2015.04.083. Epub 2015 May 6. Int J Surg. 2015. PMID: 25958296 Free article. Review.
Laparoscopic cholecystectomy (LC) is now considered the gold standard of therapy for symptomatic cholelithiasis and chronic cholecystitis. However no definitive data on its use in AC has been published. ...
Laparoscopic cholecystectomy (LC) is now considered the gold standard of therapy for symptomatic cholelithiasis and chronic cholecyst …
Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
He L, Wang J, Ping F, Yang N, Huang J, Li Y, Xu L, Li W, Zhang H. He L, et al. JAMA Intern Med. 2022 May 1;182(5):513-519. doi: 10.1001/jamainternmed.2022.0338. JAMA Intern Med. 2022. PMID: 35344001 Free PMC article.
Secondary outcomes were biliary diseases, biliary cancer, cholecystectomy, cholecystitis, and cholelithiasis. Data analyses were performed from August 5, 2021, to September 3, 2021. ...Among all included trials, randomization to GLP-1 RA treatment was associated with incre …
Secondary outcomes were biliary diseases, biliary cancer, cholecystectomy, cholecystitis, and cholelithiasis. Data analyses were perf …
Management of symptomatic cholelithiasis: a systematic review.
Shenoy R, Kirkland P, Hadaya JE, Tranfield MW, DeVirgilio M, Russell MM, Maggard-Gibbons M. Shenoy R, et al. Syst Rev. 2022 Dec 12;11(1):267. doi: 10.1186/s13643-022-02135-8. Syst Rev. 2022. PMID: 36510302 Free PMC article.
BACKGROUND: Symptomatic cholelithiasis is a common surgical disease and accounts for half of the over one million cholecystectomies performed in the USA annually. ...Providing appropriate and timely treatment for symptomatic cholelithiasis is important to streamline …
BACKGROUND: Symptomatic cholelithiasis is a common surgical disease and accounts for half of the over one million cholecystectomies p …
Acute cholecystitis.
Halpin V. Halpin V. BMJ Clin Evid. 2014 Aug 20;2014:0411. BMJ Clin Evid. 2014. PMID: 25144428 Free PMC article. Review.
Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials.
He L, Wang J, Ping F, Yang N, Huang J, Li W, Xu L, Zhang H, Li Y. He L, et al. BMJ. 2022 Jun 28;377:e068882. doi: 10.1136/bmj-2021-068882. BMJ. 2022. PMID: 35764326 Free PMC article.
MAIN OUTCOME MEASURES: Composite of gallbladder or biliary diseases, cholecystitis, cholelithiasis, and biliary diseases. DATA EXTRACTION AND DATA SYNTHESIS: Two reviewers independently extracted the data and assessed the quality of the studies. ...Compared with placebo or …
MAIN OUTCOME MEASURES: Composite of gallbladder or biliary diseases, cholecystitis, cholelithiasis, and biliary diseases. DATA EXTRAC …
Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis.
Goltstein LCMJ, Grooteman KV, Rocco A, Holleran G, Frago S, Salgueiro PS, Aparicio T, Scaglione G, Chetcuti Zammit S, Prados-Manzano R, Benamouzig R, Nardone G, McNamara D, Benallaoua M, Michopoulos S, Sidhu R, Kievit W, Drenth JPH, van Geenen EJM. Goltstein LCMJ, et al. Lancet Gastroenterol Hepatol. 2021 Nov;6(11):922-932. doi: 10.1016/S2468-1253(21)00262-4. Epub 2021 Sep 9. Lancet Gastroenterol Hepatol. 2021. PMID: 34508668
The most common adverse events were loose stools (seven [3%] of 212), cholelithiasis (five [2%]), flatulence (four [2%]), and administration site reactions (erythema, five [2%]). ...
The most common adverse events were loose stools (seven [3%] of 212), cholelithiasis (five [2%]), flatulence (four [2%]), and adminis …
ASYMPTOMATIC CHOLELITHIASIS: EXPECTANT OR CHOLECYSTECTOMY. A SYSTEMATIC REVIEW.
Alves JR, Klock DM, Ronzani FG, Santos SLD, Amico EC. Alves JR, et al. Arq Bras Cir Dig. 2023 Jul 17;36:e1747. doi: 10.1590/0102-672020230029e1747. eCollection 2023. Arq Bras Cir Dig. 2023. PMID: 37466567 Free PMC article.
BACKGROUND: Asymptomatic cholelithiasis is a highly prevalent disease, and became more evident after the currently greater access to imaging tests. ...AIMS: To seek the best evidence in order to indicate prophylactic cholecystectomy or conservative treatment (clinical foll …
BACKGROUND: Asymptomatic cholelithiasis is a highly prevalent disease, and became more evident after the currently greater access to …
Non-alcoholic Fatty Liver Disease and Gallstones: A Systematic Review.
Slouha E, Biput SJ, Kuteyi A, Kalloo AE, Gorantla VR. Slouha E, et al. Cureus. 2023 Sep 11;15(9):e45027. doi: 10.7759/cureus.45027. eCollection 2023 Sep. Cureus. 2023. PMID: 37829934 Free PMC article. Review.
The search included the keywords 'gallstones and non-alcoholic fatty liver disease' and 'cholelithiasis and non-alcoholic fatty liver disease'. Our initial search included 10,665 articles and was narrowed down to 19 through extensive inclusion and exclusion criteria. ...
The search included the keywords 'gallstones and non-alcoholic fatty liver disease' and 'cholelithiasis and non-alcoholic fatty liver …
265 results